<?xml version="1.0" ?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:seo="http://purl.org/seo/elements/1.0/" version="2.0">
	<channel>
		<title>BetterLife Pharma Inc. News Releases</title>
		<link>https://feeds.newsfilecorp.com/company/5696</link>
		<description>Latest news from BetterLife Pharma Inc., as distributed by TMX Newsfile.</description>
		<language>en</language>
		<copyright>CopyRight (c) 2026, Newsfile Corp. All Rights Reserved.</copyright>
		<managingEditor>office@newsfilecorp.com (Newsfile Corp.)</managingEditor>
		<webMaster>office@newsfilecorp.com (Newsfile Corp.)</webMaster>
		<lastBuildDate>Fri, 20 Nov 2026 14:58:50 -0500</lastBuildDate>
		<image>
			<url>https://images.newsfilecorp.com/logos/5696.jpg</url>
			<title>BetterLife Pharma Inc. News Releases</title>
			<link>https://feeds.newsfilecorp.com/company/5696</link>
		</image>
		<atom:link rel="self" type="application/rss+xml" href="https://feeds.newsfilecorp.com/company/5696"/>
		<item xml:lang="en">
			<title>BetterLife Pharma Engages Market Maker</title>
			<link>https://www.newsfilecorp.com/release/324983/BetterLife-Pharma-Engages-Market-Maker</link>
			<description>Vancouver, British Columbia--(Newsfile Corp. - November 20, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, is pleased to announce that it has engaged Integral Wealth Securities Limited ("Integral") to provide market-making services in accordance with the policies of the Canadian Securities Exchange (the "CSE").Pursuant to the terms of the...&lt;img src="https://api.newsfilecorp.com/newsinfo/324983/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Fri, 20 Nov 2026 11:08:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/324983</guid>
		</item>
		<item xml:lang="en">
			<title>BetterLife Pharma Announces Settlement of Claim with Dr. Steven Sangha</title>
			<link>https://www.newsfilecorp.com/release/322822/BetterLife-Pharma-Announces-Settlement-of-Claim-with-Dr.-Steven-Sangha</link>
			<description> - Adoption of Advance Notice Policy -- Appointment of LifeSci Advisors - Vancouver, British Columbia--(Newsfile Corp. - November 6, 2026) - BetterLife Pharma Inc.  (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced that it has entered into a settlement agreement dated November 5, 2026 (the "Settlement Agreement") with Dr. Steven Sangha ("Dr. Sangha"), a director of...&lt;img src="https://api.newsfilecorp.com/newsinfo/322822/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Fri, 06 Nov 2026 08:00:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/322822</guid>
		</item>
		<item xml:lang="en">
			<title>BetterLife Pharma Appoints Henry Chow, CPA, CA, to Board of Directors</title>
			<link>https://www.newsfilecorp.com/release/322635/BetterLife-Pharma-Appoints-Henry-Chow-CPA-CA-to-Board-of-Directors</link>
			<description>Tony Pullen steps down from the Board and will continue with the Company as an advisor Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced that Ralph Anthony ("Tony") Pullen has resigned from the Company's Board of Directors, effective November 4, 2026, and will remain...&lt;img src="https://api.newsfilecorp.com/newsinfo/322635/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Thu, 05 Nov 2026 08:00:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/322635</guid>
			<atom:subtitle>Tony Pullen steps down from the Board and will continue with the Company as an advisor</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm</title>
			<link>https://www.newsfilecorp.com/release/321060/BetterLife-Pharma-Appoints-LifeSci-Advisors-as-Investor-Relations-Firm</link>
			<description>Engagement to support expanded investor outreach as BetterLife advances BETR-001 toward planned clinical development in 2027 Vancouver, British Columbia--(Newsfile Corp. - October 27, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced that it has retained LifeSci Advisors ("LifeSci" or "LifeSci Advisors") to support its investor...&lt;img src="https://api.newsfilecorp.com/newsinfo/321060/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 27 Oct 2026 08:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/321060</guid>
			<atom:subtitle>Engagement to support expanded investor outreach as BetterLife advances BETR-001 toward planned clinical development in 2027</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board</title>
			<link>https://www.newsfilecorp.com/release/319211/BetterLife-Pharma-Appoints-Professor-Richard-B.-Lipton-as-CoChair-of-its-Scientific-Advisory-Board</link>
			<description>Director of the Montefiore Headache Center and past President of the American Headache Society joins Professor Peter Goadsby in leading the SAB for BETR-001 Vancouver, British Columbia--(Newsfile Corp. - October 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced the appointment of Professor Richard B. Lipton, MD, as Co-Chair of its...&lt;img src="https://api.newsfilecorp.com/newsinfo/319211/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Mon, 19 Oct 2026 08:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/319211</guid>
			<atom:subtitle>Director of the Montefiore Headache Center and past President of the American Headache Society joins Professor Peter Goadsby in leading the SAB for BETR-001</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations</title>
			<link>https://www.newsfilecorp.com/release/319127/BetterLife-Pharma-Appoints-Sheila-Leitzinger-as-Head-of-Clinical-Operations</link>
			<description>Clinical development veteran to lead execution of the first-in-human study of BETR-001 ahead of programs in chronic cluster headache and chronic migraine Vancouver, British Columbia--(Newsfile Corp. - October 15, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced that Sheila Leitzinger has joined the Company as Head of Clinical Operations.In this role, Ms....&lt;img src="https://api.newsfilecorp.com/newsinfo/319127/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Thu, 15 Oct 2026 08:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/319127</guid>
			<atom:subtitle>Clinical development veteran to lead execution of the first-in-human study of BETR-001 ahead of programs in chronic cluster headache and chronic migraine</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair</title>
			<link>https://www.newsfilecorp.com/release/318738/BetterLife-Pharma-Establishes-Scientific-Advisory-Board-for-Headache-Program-Professor-Peter-Goadsby-Appointed-CoChair</link>
			<description>Brain Prize co-recipient whose research identified CGRP as a central driver of migraine joins to guide development of BETR-001 in chronic cluster headache and chronic migraine Vancouver, British Columbia--(Newsfile Corp. - October 14, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced the formation of a Scientific Advisory Board...&lt;img src="https://api.newsfilecorp.com/newsinfo/318738/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Wed, 14 Oct 2026 08:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/318738</guid>
			<atom:subtitle>Brain Prize co-recipient whose research identified CGRP as a central driver of migraine joins to guide development of BETR-001 in chronic cluster headache and chronic migraine</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha</title>
			<link>https://www.newsfilecorp.com/release/318380/BetterLife-Pharma-Addresses-Notice-of-Civil-Claim-Filed-by-Steven-Sangha</link>
			<description>Vancouver, British Columbia--(Newsfile Corp. - October 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today issued a statement regarding a Notice of Civil Claim ("Claim") filed against the Company by Steven Sangha, an independent director of BetterLife, in the Supreme Court of British Columbia on October 8, 2026.As disclosed in the Company's unaudited interim financial statements and management's discussion and analysis for July 2026,...&lt;img src="https://api.newsfilecorp.com/newsinfo/318380/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Fri, 09 Oct 2026 15:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/318380</guid>
		</item>
		<item xml:lang="en">
			<title>BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting</title>
			<link>https://www.newsfilecorp.com/release/316698/BetterLife-Pharma-Announces-Rescheduling-and-Reclassification-of-Annual-General-Meeting-to-Annual-General-and-Special-Meeting</link>
			<description>Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, today announced that its upcoming Annual General Meeting ("AGM"), originally scheduled for October 14, 2026, has been rescheduled and reclassified as an Annual General and Special Meeting ("AGSM").  The rescheduled meeting will...&lt;img src="https://api.newsfilecorp.com/newsinfo/316698/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 29 Sep 2026 17:59:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/316698</guid>
		</item>
		<item xml:lang="en">
			<title>BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants</title>
			<link>https://www.newsfilecorp.com/release/314747/BetterLife-Pharma-Inc.-Announces-Closing-of-US100-Million-Public-Offering-of-Common-Shares-and-PreFunded-Warrants</link>
			<description>Vancouver, British Columbia--(Newsfile Corp. - September 17, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce that it has closed its previously announced public offering (the "Offering") of common shares of the Company ("Common Shares") and pre-funded common share purchase warrants of the Company ("Pre-Funded Warrants" and, together with the Common Shares, the...&lt;img src="https://api.newsfilecorp.com/newsinfo/314747/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Thu, 17 Sep 2026 10:41:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/314747</guid>
		</item>
	</channel>
</rss>
